AC Immune (ACIU) Quick Ratio

This chart shows the market price of AC Immune (ACIU) at 0.92. AC Immune relies on professional Swiss management, which ensures transparency regarding plans to develop treatments for Parkinson's and Alzheimer's. The business strategy is based on synergy with pharmaceutical industry leaders to develop advanced diagnostic methods. Current growth is driven by the creation of relevant therapeutic solutions in the field of neurodegeneration.

Developing innovative antibodies for the therapy of neurodegenerative diseases requires significant R&D capital expenditures. This metric excludes low-liquidity inventories, focusing exclusively on cash and accounts receivable relative to short-term liabilities. Such a strict filter allows for an assessment of the issuer's real solvency without accounting for warehouse stocks. By analyzing the quick ratio, an investor determines the ability of AC Immune (ACIU) to maintain operational activities during recessionary periods.